Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by ...

Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...

Learn More » For years, Eli Lilly has been generating solid growth numbers -- but lately, they've been accelerating rapidly. The company is coming off a solid quarter where its revenue rose by 45 ...

Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

Eli Lilly and Company (NYSE: LLY) will participate in TD Cowen's 45th Annual Health Care Conference on March 4, 2025. Jake Van Naarden, executive vice president and president, Lilly Oncology ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Eli Lilly has said it is seeking permission to build a new biopharmaceutical manufacturing facility in Ireland that will be used to produce active ingredients for its biologic medicines ...

It is tailored to patients being treated with Lilly's oncology drugs – which include blockbuster CDK 4/ 6 inhibitor Verzenio (abemaciclib) for hormone receptor-positive, HER2-negative breast ...